Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | The role of allogeneic stem cell transplantation in CLL

Peter Hillmen • 9 Jun 2016
EHA 2016
Chronic Lymphocytic Leukemia

Peter Hillmen, MBChb, PhD, FRCP, FRCPath from St. James’ University Hospital, Leeds, UK discusses allogeneic stem cell transplantation for chronic lymphocytic leukemia (CLL). According to Prof. Hillmen, allogeneic stem cell transplantation is the only therapy that can cure a minority of patients. However, there are side effects associated with a transplant, such as graft-versus-host disease (GvHD), and therefore it is not the treatment of choice.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

More from Peter Hillmen

1:55
Key updates from the interim analysis of the FLAIR trial
Peter Hillmen • 10 Jun 2022
1:03
CLL trial updates from EHA 2022
Peter Hillmen • 10 Jun 2022
1:19
Acalabrutinib vs ibrutinib in previously untreated high-risk CLL
Peter Hillmen • 10 Jun 2022
1:40
The role of MRD in decision-making in CLL
Peter Hillmen • 10 Jun 2022

Related Videos

3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
Richter’s transformation: biology & ongoing trials in the field
Carsten Niemann et al. • 25 Mar 2024
The content of VJHemOnc is intended for healthcare professionals